2024-04-012025-03-312025-03-31falseSC395958ELMORE EYECARE LTD.2025-09-23falseiso4217:GBPxbrli:pureSC3959582024-03-31SC3959582025-03-31SC3959582024-04-012025-03-31SC3959582023-03-31SC3959582024-03-31SC3959582023-04-012024-03-31SC395958bus:SmallEntities2024-04-012025-03-31SC395958bus:AuditExempt-NoAccountantsReport2024-04-012025-03-31SC395958bus:AbridgedAccounts2024-04-012025-03-31SC395958bus:PrivateLimitedCompanyLtd2024-04-012025-03-31SC395958core:WithinOneYear2025-03-31SC395958core:AfterOneYear2025-03-31SC395958core:WithinOneYear2024-03-31SC395958core:AfterOneYear2024-03-31SC395958core:ShareCapital2025-03-31SC395958core:SharePremium2025-03-31SC395958core:RevaluationReserve2025-03-31SC395958core:OtherReservesSubtotal2025-03-31SC395958core:RetainedEarningsAccumulatedLosses2025-03-31SC395958core:ShareCapital2024-03-31SC395958core:SharePremium2024-03-31SC395958core:RevaluationReserve2024-03-31SC395958core:OtherReservesSubtotal2024-03-31SC395958core:RetainedEarningsAccumulatedLosses2024-03-31SC395958core:LandBuildings2025-03-31SC395958core:PlantMachinery2025-03-31SC395958core:Vehicles2025-03-31SC395958core:FurnitureFittings2025-03-31SC395958core:OfficeEquipment2025-03-31SC395958core:NetGoodwill2025-03-31SC395958core:IntangibleAssetsOtherThanGoodwill2025-03-31SC395958core:ListedExchangeTraded2025-03-31SC395958core:UnlistedNon-exchangeTraded2025-03-31SC395958core:LandBuildings2024-03-31SC395958core:PlantMachinery2024-03-31SC395958core:Vehicles2024-03-31SC395958core:FurnitureFittings2024-03-31SC395958core:OfficeEquipment2024-03-31SC395958core:NetGoodwill2024-03-31SC395958core:IntangibleAssetsOtherThanGoodwill2024-03-31SC395958core:ListedExchangeTraded2024-03-31SC395958core:UnlistedNon-exchangeTraded2024-03-31SC395958core:LandBuildings2024-04-012025-03-31SC395958core:PlantMachinery2024-04-012025-03-31SC395958core:Vehicles2024-04-012025-03-31SC395958core:FurnitureFittings2024-04-012025-03-31SC395958core:OfficeEquipment2024-04-012025-03-31SC395958core:NetGoodwill2024-04-012025-03-31SC395958core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-31SC395958core:ListedExchangeTraded2024-04-012025-03-31SC395958core:UnlistedNon-exchangeTraded2024-04-012025-03-31SC395958core:MoreThanFiveYears2024-04-012025-03-31SC395958core:Non-currentFinancialInstruments2025-03-31SC395958core:Non-currentFinancialInstruments2024-03-31SC395958dpl:CostSales2024-04-012025-03-31SC395958dpl:DistributionCosts2024-04-012025-03-31SC395958core:LandBuildings2024-04-012025-03-31SC395958core:PlantMachinery2024-04-012025-03-31SC395958core:Vehicles2024-04-012025-03-31SC395958core:FurnitureFittings2024-04-012025-03-31SC395958core:OfficeEquipment2024-04-012025-03-31SC395958dpl:AdministrativeExpenses2024-04-012025-03-31SC395958core:NetGoodwill2024-04-012025-03-31SC395958core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-31SC395958dpl:GroupUndertakings2024-04-012025-03-31SC395958dpl:ParticipatingInterests2024-04-012025-03-31SC395958dpl:GroupUndertakingscore:ListedExchangeTraded2024-04-012025-03-31SC395958core:ListedExchangeTraded2024-04-012025-03-31SC395958dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-04-012025-03-31SC395958core:UnlistedNon-exchangeTraded2024-04-012025-03-31SC395958dpl:CostSales2023-04-012024-03-31SC395958dpl:DistributionCosts2023-04-012024-03-31SC395958core:LandBuildings2023-04-012024-03-31SC395958core:PlantMachinery2023-04-012024-03-31SC395958core:Vehicles2023-04-012024-03-31SC395958core:FurnitureFittings2023-04-012024-03-31SC395958core:OfficeEquipment2023-04-012024-03-31SC395958dpl:AdministrativeExpenses2023-04-012024-03-31SC395958core:NetGoodwill2023-04-012024-03-31SC395958core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-31SC395958dpl:GroupUndertakings2023-04-012024-03-31SC395958dpl:ParticipatingInterests2023-04-012024-03-31SC395958dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-31SC395958core:ListedExchangeTraded2023-04-012024-03-31SC395958dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-31SC395958core:UnlistedNon-exchangeTraded2023-04-012024-03-31SC395958core:NetGoodwill2025-03-31SC395958core:IntangibleAssetsOtherThanGoodwill2025-03-31SC395958core:LandBuildings2025-03-31SC395958core:PlantMachinery2025-03-31SC395958core:Vehicles2025-03-31SC395958core:FurnitureFittings2025-03-31SC395958core:OfficeEquipment2025-03-31SC395958core:AfterOneYear2025-03-31SC395958core:WithinOneYear2025-03-31SC395958core:ListedExchangeTraded2025-03-31SC395958core:UnlistedNon-exchangeTraded2025-03-31SC395958core:ShareCapital2025-03-31SC395958core:SharePremium2025-03-31SC395958core:RevaluationReserve2025-03-31SC395958core:OtherReservesSubtotal2025-03-31SC395958core:RetainedEarningsAccumulatedLosses2025-03-31SC395958core:NetGoodwill2024-03-31SC395958core:IntangibleAssetsOtherThanGoodwill2024-03-31SC395958core:LandBuildings2024-03-31SC395958core:PlantMachinery2024-03-31SC395958core:Vehicles2024-03-31SC395958core:FurnitureFittings2024-03-31SC395958core:OfficeEquipment2024-03-31SC395958core:AfterOneYear2024-03-31SC395958core:WithinOneYear2024-03-31SC395958core:ListedExchangeTraded2024-03-31SC395958core:UnlistedNon-exchangeTraded2024-03-31SC395958core:ShareCapital2024-03-31SC395958core:SharePremium2024-03-31SC395958core:RevaluationReserve2024-03-31SC395958core:OtherReservesSubtotal2024-03-31SC395958core:RetainedEarningsAccumulatedLosses2024-03-31SC395958core:NetGoodwill2023-03-31SC395958core:IntangibleAssetsOtherThanGoodwill2023-03-31SC395958core:LandBuildings2023-03-31SC395958core:PlantMachinery2023-03-31SC395958core:Vehicles2023-03-31SC395958core:FurnitureFittings2023-03-31SC395958core:OfficeEquipment2023-03-31SC395958core:AfterOneYear2023-03-31SC395958core:WithinOneYear2023-03-31SC395958core:ListedExchangeTraded2023-03-31SC395958core:UnlistedNon-exchangeTraded2023-03-31SC395958core:ShareCapital2023-03-31SC395958core:SharePremium2023-03-31SC395958core:RevaluationReserve2023-03-31SC395958core:OtherReservesSubtotal2023-03-31SC395958core:RetainedEarningsAccumulatedLosses2023-03-31SC395958core:AfterOneYear2024-04-012025-03-31SC395958core:WithinOneYear2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:CostValuation2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-31SC395958core:Non-currentFinancialInstrumentscore:CostValuation2025-03-31SC395958core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-31SC395958core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-31SC395958core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-31SC395958core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-31SC395958core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-31SC395958core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-31SC395958core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-31SC395958core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-31SC395958core:Non-currentFinancialInstrumentscore:CostValuation2024-03-31SC395958core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-31SC395958core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-31SC395958core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-31SC395958core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-31SC395958core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-31SC395958core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-31SC395958core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-31SC395958core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-31SC395958bus:Director12024-04-012025-03-31SC395958bus:Director22024-04-012025-03-31

ELMORE EYECARE LTD.

Registered Number
SC395958
(Scotland)

Unaudited Financial Statements for the Year ended
31 March 2025

ELMORE EYECARE LTD.
Company Information
for the year from 1 April 2024 to 31 March 2025

Directors

BROWN, Julie
BROWN, Scott Gordon

Registered Address

21 The Murray Square
East Kilbride
Glasgow
G75 0BH

Registered Number

SC395958 (Scotland)
ELMORE EYECARE LTD.
Balance Sheet as at
31 March 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets317,13422,601
17,13422,601
Current assets
Stocks8,0458,910
Debtors412,66714,150
Current asset investments141,219141,219
Cash at bank and on hand89,213102,173
251,144266,452
Creditors amounts falling due within one year5(17,771)(16,907)
Net current assets (liabilities)233,373249,545
Total assets less current liabilities250,507272,146
Creditors amounts falling due after one year6-(8,681)
Net assets250,507263,465
Capital and reserves
Called up share capital11
Profit and loss account250,506263,464
Shareholders' funds250,507263,465
The financial statements were approved and authorised for issue by the Board of Directors on 23 September 2025, and are signed on its behalf by:
BROWN, Julie
Director
BROWN, Scott Gordon
Director

Registered Company No. SC395958
ELMORE EYECARE LTD.
Notes to the Financial Statements
for the year ended 31 March 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20252024
Average number of employees during the year33
3.Tangible fixed assets

Total

£
Cost or valuation
At 01 April 2445,771
Additions245
At 31 March 2546,016
Depreciation and impairment
At 01 April 2423,170
Charge for year5,712
At 31 March 2528,882
Net book value
At 31 March 2517,134
At 31 March 2422,601
4.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables12,27912,945
Other debtors3881,205
Total12,66714,150
5.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables4,9351,725
Bank borrowings and overdrafts-10,648
Taxation and social security8,2353,234
Other creditors4,6011,300
Total17,77116,907
6.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts-8,681
Total-8,681
7.Directors advances, credits and guarantees
At the year-end, there was a balance due to the Directors of £3,301 from Elmore Eyecare Ltd (2024: £Nil). This loan is interest-free and is repayable on demand.
8.Controlling party
The ultimate controlling party was Mr. Scott Brown, a Director and shareholder of the company.